1. Home
  2. HBIO vs KTTA Comparison

HBIO vs KTTA Comparison

Compare HBIO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.10

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.53

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
KTTA
Founded
1901
2020
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
18.1M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
HBIO
KTTA
Price
$6.10
$0.53
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$18.00
$3.00
AVG Volume (30 Days)
20.6K
436.1K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,176,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$8.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.28
52 Week High
$7.50
$2.06

Technical Indicators

Market Signals
Indicator
HBIO
KTTA
Relative Strength Index (RSI) 49.83 35.96
Support Level $5.91 $0.49
Resistance Level $6.79 $0.76
Average True Range (ATR) 0.34 0.05
MACD -0.03 0.00
Stochastic Oscillator 25.40 37.62

Price Performance

Historical Comparison
HBIO
KTTA

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: